Not so SMART?

The Lancet Infectious Diseases

Volumn 9, Issue 5, 2009, Pages 268-269

  Stebbing, Justin ^a   Dalgleish, Angus ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; INTERLEUKIN 6; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; HEALTH CARE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; LETTER; MEDICAL LITERATURE; MORTALITY; PRIORITY JOURNAL; PUBLICATION; RISK; UNITED STATES; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT COMPLIANCE; UNITED STATES;

EID: 64849113041     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70092-1     Document Type: Letter

References (5)

1. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
2. Kuller L.H., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5 (2008) e203
3. Tedaldi E., Peters L., Neuhaus J., et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 47 (2008) 1468-1475
4. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372 (2008) 293-299
5. Koup R.A. Reconsidering early HIV treatment and supervised treatment interruptions. PLoS Med 1 (2004) e41